ERBB2 and non-small cell lung carcinoma: Examples incorporated in the clinic include KRAS mutational status indicating response to cetuximab and panitumumab in colorectal cancer [18], [20], [21], ALK re-arrangement in non-small cell lung cancer predicting response to crizotinib [18], [20], [22] and HER2/Neu amplification or overexpression in breast cancer for eligibility for trastuzumab treatment [18], [20], [23].